Individuals taking extended-release injection naltrexone for opioid use disorder may be less likely to drop out of treatment after a single use of opioids compared with patients receiving placebo.
Patients who take prescription opioids for chronic pain may have difficulty receiving treatment as new patients at primary care clinics.
Prenatal opioid exposure may be associated with poorer cognitive and motor development in children from age 6 months to adolescence.
Lasmiditan may provide effective acute relief from migraine, with sustained improvements in freedom from pain, most bothersome symptoms, total migraine, and disability.
Administration of epidural morphine during single-injection femoral nerve block may improve pain and quality of life in patients who have undergone total knee arthroplasty.
Prescribing fewer opioid pills after surgery and providing opioid use education before surgery may reduce postoperative opioid consumption.
A virtual reality treatment developed for the treatment of phantom limb pain may reduce pain intensity and phantom sensations in some patients.
Many patients with juvenile idiopathic arthritis may experience pain interference, which can be associated with greater pain intensity, disability, and pain anxiety and less leisure-time activity.
The use of lasmiditan for the treatment of migraine may be associated with a dose-dependent incidence of mild to moderate dizziness.
The US Food and Drug Administration has provided fast-track approval for the nonclinician use of Evzio, an easy-to-use autoinjectable device with a single dose of naloxone for the reversal of opioid overdose.
